Healthy Reset or Early Warning? Bitcoin Slips from All-Time Highs as Realized Profits Spike
Bitcoin’s dip to $121,000 marks a healthy reset, not a reversal. On-chain data shows strong fundamentals that could fuel the next leg higher.
Bitcoin’s price has taken a brief step back after an impressive rally that pushed it to a new all-time high earlier this week. The crypto king now trades near $121,000, slightly below recent peaks.
Despite this dip, market analysts note that the pullback appears healthy, suggesting continued investor confidence in the long-term outlook.
Bitcoin Investors Book Profits
The Realized Profit/Loss ratio, a key on-chain metric, reveals that Bitcoin investors have been selling over the past several days. The indicator recently reached a three-month high, confirming that profit-taking has intensified after the asset’s strong price surge. This pattern is typical following an extended bullish run.
While selling has been visible, it doesn’t necessarily indicate weakening confidence. Instead, it reflects a natural correction phase as traders lock in profits. With Bitcoin’s value climbing consistently since the start of the month, a short-term cooldown allows the market to stabilize before potentially resuming its upward trajectory.
Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.
Bitcoin Realized Profit/Loss Ratio. Source:
Glassnode
From a broader perspective, Bitcoin’s macro momentum remains positive. The Network Value to Transactions (NVT) Ratio, a long-term valuation metric, shows that BTC is still significantly undervalued. The indicator has fallen to a seven-month low, suggesting that transaction volume is expanding faster than Bitcoin’s market capitalization.
This dynamic indicates strong network activity, often viewed as a bullish signal. Rising transaction levels paired with relatively slower market cap growth highlight continued user engagement and institutional adoption.
Bitcoin NVT Ratio. Source:
Glassnode
BTC Price Is Not Losing Too Much
At the time of writing, Bitcoin trades at $121,353, holding firm above the $120,000 support level. The asset sits just below the $122,000 resistance, which has become a key short-term threshold for traders watching potential breakout signals.
The recent decline can largely be attributed to profit-taking after Bitcoin reached its current all-time high of $126,199. Given the strength of current technical and on-chain indicators, BTC is likely to reclaim $122,000 and consolidate within a stable range before attempting another upward push.
Bitcoin Price Analysis. Source:
TradingView
However, if selling pressure intensifies and investors take additional profits, Bitcoin could slip below $120,000. In that case, a decline toward $117,261 remains possible, temporarily invalidating the prevailing bullish outlook.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
